STOCKHOLDERS EQUITY (Tables)

12 Months Ended

Dec. 31, 2023

STOCKHOLDERS' EQUITY [Abstract]

Warrants Outstanding

The following table summarizes information about warrants outstanding as of December 31, 2023, 2022 and 2021:

	Shares			Weighted Average Exercise Price
Warrants outstanding at December 31, 2020		4,528,160		$	2.82
Expired		-		$	-
Granted		-		$	-
Exercised		-		$	-
Warrants outstanding at December 31, 2021		4,528,160		$	2.82
Expired		(106,059	)	$	8.23
Granted		9,103,047		$	1.65
Exercised		-		$	-
Warrants outstanding at December 31, 2022		13,525,148		$	1.99
Expired		(24,800	)	$	6.37
Granted		2,391,244		$	3.26
Exercised		(3,388,686	)	$	1.65
Warrants outstanding at December 31, 2023		12,502,906		$	2.32

Schedule of Assumptions

The grant date fair values of stock options awarded during the years ended December 31, 2023, 2022 and 2021 were determined using the Black-Scholes option pricing model with the following assumptions:

	Years Ended
	December 31, 2023			December 31, 2022			December 31, 2021
Expected term	5.5-6.3 years			5.5-6.3 years			5.5-6.3 years
Volatility		68	%		68	%		68-70	%
Dividend yield		0.0			0.0			0.0
Risk-free interest rate		4.20-4.62	%		1.72-1.73	%		0.80-1.27	%

Schedule of Option Activity

The following table summarizes information about stock options outstanding as of December 31, 2023, 2022 and 2021:

	Shares			Weighted Average Exercise Price
Options outstanding, vested and expected to vest at December 31, 2020		6,922,931		$	4.40
Forfeited		(529,202	)	$	2.89
Expired		(426,557	)	$	4.91
Granted		1,895,550		$	2.14
Exercised		-		$	-
Options outstanding, vested and expected to vest at December 31, 2021		7,862,722		$	3.93
Forfeited		(31,540	)	$	2.37
Expired		(700,324	)	$	6.86
Granted		1,194,032		$	1.67
Exercised		(68,679	)	$	2.55
Options outstanding, vested and expected to vest at December 31, 2022		8,256,211		$	3.37
Forfeited		(99,345	)	$	2.73
Expired		(262,940	)	$	6.42
Granted		1,826,380		$	3.36
Exercised		(3,814,122	)	$	3.15
Options outstanding, vested and expected to vest at December 31, 2023		5,906,184		$	3.38
Options exercisable		3,410,131		$	3.79

Summary of Outstanding and Exercisable Options by Price Range

The following table summarizes additional information regarding outstanding and exercisable options under the stock option plans at December 31, 2023:

	Stock Options Outstanding								Stock Options Exercisable
Range of Exercise Prices	Options Outstanding		Weighted Average Remaining Contractual Life (Years)		Weighted Average Exercise Price		Aggregate Intrinsic Value ($000’s)		Options Outstanding		Weighted Average Remaining Contractual Life (Years)		Weighted Average Exercise Price		Aggregate Intrinsic Value ($000’s)
$1.10 - $1.67		1,175,410		7.7	$	1.60	$	3,428		590,275		7.3	$	1.56	$	1,748
$1.73 - $2.60		1,028,392		6.6	$	2.33		2,253		712,704		6.4	$	2.34		1,551
$2.67 - $4.01		2,905,506		7.4	$	3.41		3,211		1,310,276		5.3	$	3.49		1,343
$4.01 - $6.02		383,535		3.5	$	5.09		22		383,535		3.5	$	5.09		22
$6.26 - $9.39		279,841		1.1	$	8.48		-		279,841		1.1	$	8.48		-
$10.80 - $16.20		133,500		1.1	$	10.80		-		133,500		1.1	$	10.80		-
		5,906,184		6.6	$	3.38	$	8,914		3,410,131		5.2	$	3.79	$	4,664

Schedule of Unvested RSU Activity

A summary of the Company’s unvested RSU activity and related information is as follows:

	Shares			Weighted Average Grant Date Fair Value
Balance at December 31, 2020		326,000		$	2.81
Granted		4,384,744		$	1.30
Vested		(92,750	)	$	2.82
Forfeited		(132,861	)	$	2.51
Balance at December 31, 2021		4,485,133		$	1.34
Granted		1,174,266		$	1.74
Vested		(2,727,412	)	$	1.25
Forfeited		(65,000	)	$	1.40
Balance at December 31, 2022		2,866,987		$	1.59
Granted		3,389,760		$	3.42
Vested		(1,199,445	)	$	1.63
Forfeited		(400,005	)	$	2.71
Balance at December 31, 2023		4,657,297		$	2.81

Schedule of Stock-Based Compensation Expense

Total stock-based compensation expense for all awards granted under the Company’s equity incentive plans for the years ended December 31, 2023, 2022 and 2021 was as follows (in thousands):

	2023		2022		2021
Research and development	$	40	$	19	$	154
Plasma center operating expenses		146		82		60
Selling, general and administrative		5,331		4,717		2,958
Cost of product revenue		670		397		316
Total stock-based compensation expense	$	6,187	$	5,215	$	3,488